Ask yourself to a higher standard.
Release time:
2021-02-10
requires himself to use higher standards for the outstanding employee of
Group Company in 2020. Dong Li
of Anhui New Jianfeng North Card Pharmaceutical Co., Ltd. in 2020 , I actively promoted the development of new products and local transformation on the basis of maintaining the smooth production of original products, and made some achievements in technical projects, product maintenance, technological innovation and new project construction.
In this year, I participated in the completion of the synthesis route investigation of trifluorobenzoyl chloride and L-aminopropanol, the quotation and implementation of QG101-23-0 and LM34-17 projects, and the compilation and improvement of relevant data of many new projects such as M225, M15 and Moxicyclic. Assist in the laboratory pilot verification of immobilized enzyme for M255 project, and pilot test of nitrification reaction pipeline for M58 project in KG laboratory, each step of moxifloxacin hydrochloride project includes small test, pilot test preparation and three batches of process verification. Optimize M255 alkalization process and replace methanol with water for reaction. According to the analysis of the current pilot test in KG laboratory, the reaction time is shortened from 18 hours to 2 hours. At the same time, the influence of salt on the rectification yield of the product is effectively reduced, the single batch yield is increased by 5%, and the methanol removal cost is about 22 yuan/KG; product line design for hydrogenation workshop and API workshop, and cooperate with engineering department and procurement for equipment purchase and project bidding.
As far as I am concerned, in my daily work, I just try my best to do my job well. When I encounter problems, I will consult modestly until it is completely solved. I will actively carry out work exchanges with various departments and colleagues to promote all The work went smoothly. In 2020, my work was recognized by the company, which is a great encouragement to me. At the same time, this honor is also heavy and is the spur and motivation for my future work. In 2021, I will redouble my efforts, strictly demand myself with higher standards, uphold the working attitude of "open-minded, enthusiastic, careful and patient", study hard and devote myself to business. I will work hard from the following aspects:
1. strive to do a good job in research and development, and try to reduce the cost of existing products. While maintaining the quality of the old products, the product chain is derived and the raw material process is developed. For example, the two-acid process can develop the raw material process of L-aminopropanol and tetrafluorobenzoyl chloride, master the core lifeblood, and enhance the competitiveness of products and further reduce costs. New products speed up process innovation, such as the development of the immobilized enzyme process and the optimization of the alkalization process of moxi small ring, complete the workshop trial production as soon as possible, and realize the effective conversion of technology and profit.
2. accelerate the development and transformation of new products and technologies. Actively cooperate with scientific research institutions to promote the development of new products and enhance the competitive advantage of new varieties of factories; promote the construction of small molecule targeting research institute projects, enhance the scientific research strength of enterprises, and further accelerate the incubation and implementation of new projects.
3. Growth Phase II project construction, faster and better to promote the second phase of the project in Anhui New Peak North Card settled production.
We are facing more challenges and opportunities in the new year. I will continue to do my job steadily and diligently, dare to take responsibility, work hard, and continue to contribute to the growth and development of Shanghai North Carolina. Meager power, but also make my own efforts for the peak cause. (According to Dong Li's speech at the summary and commendation meeting of the group company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page